NCT04506242 2020-09-09
Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Affiliated Hospital of North Sichuan Medical College